F091 Navigating Prior Authorization in Dermatology: Challenges, Innovations, and Solutions
DESCRIPTION
Prior authorization (PA) for dermatologic medications and procedures presents a significant and growing challenge for both providers and patients. This session will provide a comprehensive overview of the current state of prior authorization in dermatology, delve into its impact on patient care and practice workflow, and explore the crucial role of technology in streamlining this complex process.
Key areas covered will include:
•The burden of prior authorization: An in-depth look at the prevalence of PA in dermatology, including the time and resources it consumes, and its consequences for treatment delays and patient outcomes. This segment will highlight the emotional and financial toll on patients and practices alike.
•Real-world case studies of current state Academy tools, support, and advocacy: Illustrative examples of how PA impacts access to essential dermatologic therapies, including biologics, oral medications, and innovative treatments. We will also discuss the tools, capabilities, and advocacy resources that the AAD is implementing to address these challenges.
•Potential role of technology: A focus on how electronic prior authorization (ePA) systems, artificial intelligence, and clinical decision support tools can improve efficiency, reduce administrative burden, and optimize patient care. We will evaluate whether any of these technologies are ready for prime time in dermatology practices.
•Future directions: Expert perspectives on the evolving landscape of healthcare technologies, including ambient listening capabilities and other innovations that may shape the future of PA in dermatology.
LEARNING OBJECTIVES
Describe the current challenges and complexities of prior authorization in dermatology.
Identify practical strategies for navigating the PA process and advocating for patients.
Discuss how technology can be leveraged to streamline PA and improve patient access to care.
SCHEDULE
1:00 PM
Session Introduction: Taming the Beast
Justin Ko, MD, MBA, FAAD
1:10 PM
Peeking Under the Hood: Current landscape, burdens on stakeholders, and what the AAD is doing for you!
Ryan Walter Hick, MD, FAAD
1:30 PM
Lessons from the Clinics--What are health system and dermatology practice approaches to the prior authorization burden?
Angela Lamb, MD, FAAD
1:50 PM
The Tech Arms Race: How can Tech & AI Solutions Support PA and Practice Administrative Burdens?
Faranak Kamangar, MD, FAAD
2:10 PM
Ask the Dermatoethicist! What are ethical considerations relevant for prior authorizations and the use of technology and AI to support PAs?
Jane Margaret Grant-Kels, MD, FAAD
2:30 PM
Moderated Panel Discussion and Audience Q&A
DIRECTOR
Justin Ko, MD, MBA, FAAD
CO-DIRECTOR
Milad Eshaq, MD, FAAD
SPEAKERS
Jane Margaret Grant-Kels, MD, FAAD
Ryan Walter Hick, MD, FAAD
Faranak Kamangar, MD, FAAD
Angela Lamb, MD, FAAD
DISCLOSURES
Milad Eshaq, MD, FAAD
No financial relationships exist with ineligible companies.
Jane Margaret Grant-Kels, MD, FAAD
No financial relationships exist with ineligible companies.
Ryan Walter Hick, MD, FAAD
PP Capital – Stockholder(No Compensation Received); Sonic Healthcare – Stockholder(No Compensation Received); Stingray Therapeutics – Stockholder(No Compensation Received);
Faranak Kamangar, MD, FAAD
No financial relationships exist with ineligible companies.
Justin Ko, MD, MBA, FAAD
AbbVie – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Fees); Enspectra Health – Consultant(Fees); Google Research – Investigator(Grants/Research Funding); Hims – Consultant(Fees); Orlucent – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees); Skin Analytics – Consultant(Fees);
Angela Lamb, MD, FAAD
No financial relationships exist with ineligible companies.